{
    "id": 4143,
    "fullName": "CTNNB1 S33Y",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "CTNNB1 S33Y lies within the ubiquitination recognition motif of the Ctnnb1 protein and occurs at a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 15064718). S33Y confers a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1, increased Ctnnb1-driven transcription, and increased proliferation of cells in culture (PMID: 18757411).",
            "references": [
                {
                    "id": 408,
                    "pubMedId": 15064718,
                    "title": "Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15064718"
                },
                {
                    "id": 2332,
                    "pubMedId": 18757411,
                    "title": "Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18757411"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1499,
        "geneSymbol": "CTNNB1",
        "terms": [
            "CTNNB1",
            "armadillo",
            "CTNNB",
            "EVR7",
            "MRD19",
            "NEDSDV"
        ]
    },
    "variant": "S33Y",
    "createDate": "03/26/2015",
    "updateDate": "03/28/2017",
    "referenceTranscriptCoordinates": {
        "id": 138040,
        "transcript": "NM_001098210",
        "gDna": "chr3:g.41224610C>A",
        "cDna": "c.98C>A",
        "protein": "p.S33Y",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13859,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y demonstrated increased sensitivity to MPI-0479605 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3950,
                "profileName": "CTNNB1 S33Y"
            },
            "therapy": {
                "id": 3458,
                "therapyName": "MPI-0479605",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13850,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to BAY1161909 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3950,
                "profileName": "CTNNB1 S33Y"
            },
            "therapy": {
                "id": 3445,
                "therapyName": "BAY1161909",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13834,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal carcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to NTRC 0066-0 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3950,
                "profileName": "CTNNB1 S33Y"
            },
            "therapy": {
                "id": 3461,
                "therapyName": "NTRC 0066-0",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13841,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to NMS-P715 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3950,
                "profileName": "CTNNB1 S33Y"
            },
            "therapy": {
                "id": 3107,
                "therapyName": "NMS-P715",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13839,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3950,
                "profileName": "CTNNB1 S33Y"
            },
            "therapy": {
                "id": 3451,
                "therapyName": "Mps-BAY2b",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13858,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y demonstrated increased sensitivity to Mps1-IN-1 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3950,
                "profileName": "CTNNB1 S33Y"
            },
            "therapy": {
                "id": 3424,
                "therapyName": "Mps1-IN-1",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13851,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to BAY1217389 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3950,
                "profileName": "CTNNB1 S33Y"
            },
            "therapy": {
                "id": 3446,
                "therapyName": "BAY1217389",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8119,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Odomzo (sonidegib) inhibited survival of tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing CTNNB1 S33Y in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26162,
                "profileName": "CTNNB1 S33Y PTCH1 inact mut"
            },
            "therapy": {
                "id": 1428,
                "therapyName": "Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3950,
            "profileName": "CTNNB1 S33Y",
            "profileTreatmentApproaches": [
                {
                    "id": 8026,
                    "name": "Tankyrase Inhibitor",
                    "profileName": "CTNNB1 S33Y"
                },
                {
                    "id": 8025,
                    "name": "PDPK1 Inhibitor",
                    "profileName": "CTNNB1 S33Y"
                },
                {
                    "id": 8024,
                    "name": "CTNNB1 Inhibitor",
                    "profileName": "CTNNB1 S33Y"
                }
            ]
        },
        {
            "id": 26162,
            "profileName": "CTNNB1 S33Y PTCH1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 138042,
            "transcript": "XM_005264886",
            "gDna": "chr3:g.41224610C>A",
            "cDna": "c.98C>A",
            "protein": "p.S33Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 138038,
            "transcript": "NM_001904",
            "gDna": "chr3:g.41224610C>A",
            "cDna": "c.98C>A",
            "protein": "p.S33Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 138039,
            "transcript": "NM_001098209",
            "gDna": "chr3:g.41224610C>A",
            "cDna": "c.98C>A",
            "protein": "p.S33Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 138040,
            "transcript": "NM_001098210",
            "gDna": "chr3:g.41224610C>A",
            "cDna": "c.98C>A",
            "protein": "p.S33Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 138043,
            "transcript": "XM_017005738",
            "gDna": "chr3:g.41224610C>A",
            "cDna": "c.98C>A",
            "protein": "p.S33Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 138041,
            "transcript": "XM_006712985",
            "gDna": "chr3:g.41224610C>A",
            "cDna": "c.98C>A",
            "protein": "p.S33Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}